AsclepiX Therapeutics is revolutionizing the treatment of retinal diseases and cancer with a singular focus on the design, development, and delivery of novel peptides with the power to inhibit proven key disease pathways. Their peptide drug candidates tap into the body’s powerful mechanisms of maintaining homeostasis, the fundamental principle of biology to seek and maintain a condition of equilibrium or stability.

Biotechnology

AsclepiX Therapeutics

Robert J. Dempsey

Sarah Pettorsson

Jill Vazzano Tierney

Josh Barer

Ben Askew

Jordan J. Green

Amir Shojaei

AsclepiX Therapeutics' CEO and Executive Team includes Theresa Heah.

CEO and Executive Team

Board of Directors

Leadership Team

CEO and Executive Team

About

Other teams at AsclepiX Therapeutics

Board of Directors

Leadership Team